NCT00455195 - Late-Onset Treatment Study Extension Protocol | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

November 30, 2008

Conditions

Pompe Disease (Late-Onset)Glycogen Storage Disease Type II (GSD-II)Glycogenesis Type IIAcid Maltase Deficiency (AMD)

Interventions

BIOLOGICAL

alglucosidase alfa

IV infusion of 20 mg/kg; every other week (qow)

Trial Locations (31)

Unknown

Anchorage

Phoenix

Beverly Hills

San Diego

Washington D.C.

Coral Springs

Gainesville

Sarasota

Chicago

Kansas City

New Orleans

Boston

Omaha

New York

Durham

Cincinnati

Toledo

Tulsa

Portland

Philadelphia

Pittsburgh

Greenville

Dallas

San Antonio

Seattle

Green Bay

Westmead

Calgary

Sherbrooke

Paris

Rotterdam

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY